Danish Centre for Strategic Research in Type 2 Diabetes (DD2) project cohort of newly diagnosed patients with type 2 diabetes: a cohort profile

Diana Hedevang Christensen, Sia Kromann Nicolaisen, Klára Berencsi, Henning Beck-Nielsen, Jørgen Rungby, Søren Friborg, Ivan Brandslund, Jens Sandahl Christiansen, Allan Vaag, Henrik Toft Sørensen, Jens Steen Nielsen, Reimar Wernich Thomsen, Diana Hedevang Christensen, Sia Kromann Nicolaisen, Klára Berencsi, Henning Beck-Nielsen, Jørgen Rungby, Søren Friborg, Ivan Brandslund, Jens Sandahl Christiansen, Allan Vaag, Henrik Toft Sørensen, Jens Steen Nielsen, Reimar Wernich Thomsen

Abstract

Purpose: The aim of this article is to provide a detailed description of the ongoing nationwide Danish Centre for Strategic Research in Type 2 Diabetes (DD2) project cohort and biobank. The DD2 cohort continuously enrols newly diagnosed patients with type 2 diabetes (T2D) throughout Denmark. The overall goal of the DD2 project is to establish a large and data-rich T2D cohort that can serve as a platform for exhaustive T2D research including (1) improved genotypic and phenotypic characterisation of T2D, (2) intervention studies of more individualised T2D treatment, (3) pharmacoepidemiological studies and (4) long-term follow-up studies on predictors of T2D complications and prognosis.

Participants: Between 2010 and 2016, 7011 individuals with T2D have been enrolled and assessed at baseline. Information collected include interview data (eg, body weight at age 20 years, physical activity and alcohol consumption), clinical examination data (eg, hip-waist ratio and resting heart rate) and biological samples (whole blood, DNA, plasma and urine) stored at -80°C and currently analysed for a range of biomarkers and genotypes.

Findings to date: Registry linkage has provided extensive supplemental continuous data on glycosylated haemoglobin A, lipids, albuminuria, blood pressure, smoking habits, body mass index, primary care contacts, hospital diagnoses and procedures, medication use, cancer and mortality. Cross-sectional associations between biomarkers, family history, anthropometric and lifestyle measures and presence of complications at baseline have been reported.

Future plans: During 2016, a detailed follow-up questionnaire has been answered by 85% of initial participants, providing follow-up information on baseline variables and on presence of diabetic neuropathy. The DD2 cohort has now been followed for a total of 18 862 person-years, and nested intervention trials and follow-up studies are ongoing. In the future, the cohort will serve as a strong national and international resource for recruiting patients to nested case studies, clinical trials, postmarketing surveillance, large-scale genome studies and follow-up studies of T2D complications.

Keywords: epidemiology; general diabetes; genetics.

Conflict of interest statement

Competing interests: The salary of DHC is paid by the International Diabetic Neuropathy Consortium (IDNC) research programme, which is supported by a Novo Nordisk Foundation Challenge Programme grant (grant number NNF14OC0011633). AV started employment at AstraZeneca in March 2016. JSC has served on advisory boards and speaker panels for Novo Nordisk. The remaining authors report no personal conflicts of interest pertaining to this work. Moreover, the Department of Clinical Epidemiology, Aarhus University Hospital, participates in the IDNC research programme and is involved in the Program for Clinical Research Infrastructure (PROCRIN) established by the Lundbeck Foundation and the Novo Nordisk Foundation. The Department of Clinical Epidemiology, Aarhus University Hospital, also receives funding for other studies from companies in the form of research grants to (and administered by) Aarhus University. None of these studies have any relation to the present study.

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Figures

Figure 1
Figure 1
Enrolment sites throughout Denmark. Every circle represents an enrolment site, either at a general practitioner’s office or at an outpatient clinic. The administrative headquarter of the DD2 is in Odense (red dot). DD2, Danish Centre for Strategic Research in Type 2 Diabetes.
Figure 2
Figure 2
Flow chart of data collection in the DD2 cohort study. DD2, Danish Centre for Strategic Research in Type 2 Diabetes; DDDA, Danish Diabetes Database for Adults; HbA1c, glycosylated haemoglobin A; SF-12, 12-Item Short Form Health Survey.
Figure 3
Figure 3
Schematic overview of individual-level data linkage in the DD2 cohort using the civil registration number as personal identification. DD2, Danish Centre for Strategic Research in Type 2 Diabetes.

References

    1. Rao Kondapally Seshasai S, Kaptoge S, Thompson A, et al. . Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011;364:829–41. 10.1056/NEJMoa1008862
    1. Christensen DH, Rungby J, Thomsen RW. Nationwide trends in glucose-lowering drug use, Denmark, 1999-2014. Clin Epidemiol 2016;8:381–7. 10.2147/CLEP.S113211
    1. Steffensen C, Thomsen RW, Vaag A, et al. . The Danish Centre for Strategic Research in Type 2 Diabetes (DD2) Project: rationale and planned nationwide studies of genetic predictors, physical exercise, and individualized pharmacological treatment. Clin Epidemiol 2012;4:7–13. 10.2147/CLEP.S30188
    1. Schmidt M, Pedersen L, Sørensen HT. The Danish civil registration system as a tool in epidemiology. Eur J Epidemiol 2014;29:541–9. 10.1007/s10654-014-9930-3
    1. Nielsen JS, Thomsen RW, Steffensen C, et al. . The Danish Centre for Strategic Research in Type 2 Diabetes (DD2) study: implementation of a nationwide patient enrollment system. Clin Epidemiol 2012;4:27–36. 10.2147/CLEP.S30838
    1. Christensen H, Nielsen JS, Sørensen KM, et al. . New national Biobank of The Danish Center for Strategic Research on Type 2 Diabetes (DD2). Clin Epidemiol 2012;4:37–42. 10.2147/CLEP.S33042
    1. Thomsen RW, Friborg S, Nielsen JS, et al. . The Danish centre for strategic research in type 2 diabetes (DD2): organization of diabetes care in Denmark and supplementary data sources for data collection among DD2 study participants. Clin Epidemiol 2012;4:15–19. 10.2147/CLEP.S30082
    1. Schmidt M, Schmidt SA, Sandegaard JL, et al. . The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol 2015;7:449–90. 10.2147/CLEP.S91125
    1. Charlson ME, Pompei P, Ales KL, et al. . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–83. 10.1016/0021-9681(87)90171-8
    1. Johannesdottir SA, Horváth-Puhó E, Ehrenstein V, et al. . Existing data sources for clinical epidemiology: The Danish national database of reimbursed prescriptions. Clin Epidemiol 2012;4:303–13. 10.2147/CLEP.S37587
    1. Gjerstorff ML. The Danish cancer registry. Scand J Public Health 2011;39:42–5. 10.1177/1403494810393562
    1. Helweg-Larsen K. The Danish register of causes of death. Scand J Public Health 2011;39:26–9. 10.1177/1403494811399958
    1. Andersen JS, Olivarius NF, Krasnik A. The Danish national health service register. Scand J Public Health 2011;39:34–7. 10.1177/1403494810394718
    1. Lab News 6/2015. Change in Proinsulin C-peptide analysis. Department of Biochemistry, Lillebaelt Hospital, Vejle, Denmark. (accessed Aug 2016).
    1. Mor A, Svensson E, Rungby J, et al. . Modifiable clinical and lifestyle factors are associated with elevated alanine aminotransferase levels in newly diagnosed type 2 diabetes patients: results from the nationwide DD2 study. Diabetes Metab Res Rev 2014;30:707–15. 10.1002/dmrr.2539
    1. Svensson E, Mor A, Rungby J, et al. . Lifestyle and clinical factors associated with elevated C-reactive protein among newly diagnosed Type 2 diabetes mellitus patients: a cross-sectional study from the nationwide DD2 cohort. BMC Endocr Disord 2014;14:74 10.1186/1472-6823-14-74
    1. Mor A, Berencsi K, Svensson E, et al. . Prescribing practices and clinical predictors of glucose-lowering therapy within the first year in people with newly diagnosed Type 2 diabetes. Diabet Med 2015;32:1546–54. 10.1111/dme.12819
    1. Svensson E, Berencsi K, Sander S, et al. . Association of parental history of type 2 diabetes with age, lifestyle, anthropometric factors, and clinical severity at type 2 diabetes diagnosis: results from the DD2 study. Diabetes Metab Res Rev 2016;32:308–15. 10.1002/dmrr.2721
    1. Steffensen C, Thomsen HH, Dekkers OM, et al. . Low positive predictive value of midnight salivary cortisol measurement to detect hypercortisolism in type 2 diabetes. Clin Endocrinol 2016;85:202–6. 10.1111/cen.13071
    1. Ried-Larsen M, Thomsen RW, Berencsi K, et al. . Implementation of interval walking training in patients with type 2 diabetes in Denmark: rationale, design, and baseline characteristics. Clin Epidemiol 2016;8:201–9. 10.2147/CLEP.S97303
    1. Storm HH, Michelsen EV, Clemmensen IH, et al. . The Danish Cancer Registry--history, content, quality and use. Dan Med Bull 1997;44:535–9.
    1. Thygesen SK, Christiansen CF, Christensen S, et al. . The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. BMC Med Res Methodol 2011;11:83 10.1186/1471-2288-11-83
    1. Czernichow S, Kengne AP, Huxley RR, et al. . Comparison of waist-to-hip ratio and other obesity indices as predictors of cardiovascular disease risk in people with type-2 diabetes: a prospective cohort study from ADVANCE. Eur J Cardiovasc Prev Rehabil 2011;18:312–9. 10.1097/HJR.0b013e32833c1aa3
    1. Thomsen RW, Baggesen LM, Svensson E, et al. . Early glycaemic control among patients with type 2 diabetes and initial glucose-lowering treatment: a 13-year population-based cohort study. Diabetes Obes Metab 2015;17:771–80. 10.1111/dom.12484

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel